Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors

Clinical trial NCT05117138 · UNKNOWN

Trial details

NCT number: NCT05117138
Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Melanoma Non-small Cell Lung Cancer Head and Neck Squamous Cell Carcinoma

Start date: 2022-01-01
Primary completion: 2023-12-01
Enrollment: 39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.